ProCE Banner Series

Tumors Associated with Neurofibromatosis Type 1: Precision Medicine Approaches to Improve Patient Outcomes Across All Age Groups

Join us either in-person or online for this CME-certified satellite symposium held in conjunction with the Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada, featuring expert perspectives on MEK inhibition for the treatment of NF1-associated plexiform neurofibromas in pediatric and adult patients. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session.

To Register: On the events dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

  AMA
Who Should Attend

This program is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, and other healthcare professionals who care for patients with NF1-associated tumors.

All Events

Tumors Associated with Neurofibromatosis Type 1: Precision Medicine Approaches to Improve Patient Outcomes Across All Age Groups

Past Events

November

16

2023

11:45 AM - 12:45 PM Pacific Time (PT)

In-personVirtual

Vancouver Convention Center, 1055 Canada Place, Vancouver, British Columbia Canada, V6C 0C3

Topics

Agenda

  • NF1: Current State of Disease Understanding
  • MEK Inhibition in NF1-Associated Tumors
  • Practical Management Strategies in NF1
  • Clinical Trial Spotlight: Key Studies Presented at SNO 2023

Additional Info

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.


There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners to apply recent findings and integrate new and emerging agents into the treatment of patients with NF1-associated tumors.

Target Audience
This program is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, and other healthcare professionals who care for patients with NF1-associated tumors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the relevance of NF1 gene alterations and the RAS/MAPK signaling pathway in the pathogenesis of neurofibromas and other NF1-associated tumors
  • Evaluate the rationale for the use of MEK inhibiting agents and other investigational targeted therapies for the treatment of NF1-related benign and malignant tumors
  • Incorporate MEK inhibitors into treatment plans for patients with NF1-associated plexiform neurofibromas based on the latest evidence, recommendations, and individual patient and tumor characteristics
  • Apply supportive care strategies to manage both common and rare toxicities associated with MEK inhibitor therapy in NF1-associated plexiform neurofibromas
  • Assess current data on potential expanded indications and emerging agents in NF1 to prepare for efficient integration of emerging therapies into clinical practice


Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

This activity is supported by an educational grant from Alexion Pharmaceuticals.